share_log

Jim Cramer Says Treat Vaccines, Stock Market With Skepticism Monday

Jim Cramer Says Treat Vaccines, Stock Market With Skepticism Monday

吉姆·克雷默週一表示對疫苗和股市持懷疑態度
TheStreet ·  2020/11/23 15:21

Happy Monday!

週一快樂!

As of 12 P.M. ET, the Dow rose, the Nasdaq rose and the S&P rose as Wall Street was met with more positive vaccine news to kick off Thanksgiving week.

截至美國東部時間下午12點,道瓊斯指數上漲,納斯達克指數上漲,標準普爾指數上漲,華爾街迎來了更多積極的疫苗消息,拉開了感恩節周的序幕。

Referring to his previous experience navigating news around COVID testing developments, Jim Cramer said that he is approaching vaccine news and the subsequent market reaction with skepticism in his daily live show withTheStreet.

吉姆·克雷默(Jim Cramer)在談到他之前在COVID測試進展中瀏覽新聞的經歷時説,在他與The Street的日常直播節目中,他對疫苗新聞和隨後的市場反應持懷疑態度。

As mentioned previously, Cramer is less concerned with the actual vaccines and more with how the vaccine will be rolled out to the general public when approved.

如前所述,克雷默不太關心實際的疫苗,而更關心的是疫苗在獲得批准後將如何向公眾推出。

Cramer said his skepticism is derived from previous positive developments that never came to fruition, such as mass testing in Walmart( WMT ) - Get Reportparking lots. "Why should I necessarily believe this vaccine is going to be distributed right," Cramer asked.

克雷默説,他的懷疑源於之前從未取得成果的積極進展,比如沃爾瑪(Walmart)-Get Report停車場的大規模測試。克雷默問:“為什麼我一定要相信這種疫苗會得到正確的分配。”

"Let's maintain her skepticism while at the same time...being a little more positive," Cramer said. "I just don't want people to think we're buying stocks like we're all going to have a vaccine by January."

克雷默説:“讓我們保持她的懷疑態度,同時……保持積極一點。”“我只是不想讓人們認為我們在買入股票,就好像我們都會在明年1月之前接種疫苗一樣。”

Jim Cramer talks vaccines, Regeneron, Tesla, Merck, the presidential transition and more in the video below:

吉姆·克雷默在下面的視頻中談到了疫苗、Regeneron、特斯拉、默克、總統過渡等問題:

The COVID-19 vaccine candidate being developed by AstraZeneca( AZN ) - Get Reportand the University of Oxford was found in a large trial to have a 70% efficacy in preventing the virus. But when a half dose of the vaccine was followed by a full dose a month later it showed 90% effectiveness.

阿斯利康(AstraZeneca)和牛津大學(University Of Oxford)正在研發的新冠肺炎候選疫苗在一項大型試驗中被發現具有70%的預防病毒效果。但是,當半劑疫苗在一個月後全量接種時,顯示出90%的有效率。

“We see a lot of merit in this regimen and we will now start discussions with regulators into incorporating this dose combination for further clinical investigation,” said an AstraZeneca spokesman.

阿斯利康的一位發言人説:“我們看到了這種療法的許多優點,我們現在將開始與監管機構討論納入這種劑量組合,以進行進一步的臨牀研究。”

And, over the weekend, the FDA granted approval to Regeneron( REGN ) - Get Reporttreatments casirivimab and imdevimab, which the agency said can now be given together to treat mild to moderate disease in people older than age 12.

上週末,FDA批准了Regeneron(REGN)-Get Report Treatment casirivimab和imdemab,該機構表示,這兩種藥物現在可以一起用於治療12歲以上人羣的輕中度疾病。

A clinical trial of patients infected with the coronavirus showed that casirivimab and imdevimab, when given together and administered via intravenous infusion, cut down Covid-19-related hospitalizations in high-risk patients within 28 days after treatment when compared to placebo, according to FDA.

根據美國食品和藥物管理局的説法,一項對感染冠狀病毒的患者的臨牀試驗表明,與安慰劑相比,卡西維瑪和伊莫司馬聯合使用並通過靜脈輸注的方式,可以減少高危患者在治療後28天內因新冠肺炎而住院的次數。

While Cramer said Regeneron "has something great," he remains concerned about the ability for the company to manufacture the treatment at scale. "I very much believe in Regeneron; it's an incredible company, but can we get it at scale," Cramer asked.

雖然克雷默説Regeneron“有很好的東西”,但他仍然擔心該公司規模化生產治療的能力。克雷默問道:“我非常相信Regeneron;這是一家令人難以置信的公司,但我們能規模化嗎?”

Daniel Kuhn contributed reporting to this article. Latest Videos From TheStreet and Jim Cramer:

丹尼爾·庫恩(Daniel Kuhn)對本文也有貢獻。來自TheStreet和Jim Cramer的最新視頻:

AstraZeneca, Oxford Say Phase 2 Shows Immune Response: Latest on Race to COVID VaccineJim Cramer Gives Investors Two Unique Stock Pick IdeasBest Black Friday Deals: WalletHub's Top 10 RetailersJim Cramer: How to Balance Stay-At-Home and Return to Normal Plays

阿斯利康,牛津説,第二階段顯示出免疫反應:最新的COVID疫苗競賽吉姆·克雷默給投資者兩個獨特的選股想法最佳黑色星期五交易:WalletHub的十大零售商吉姆·克雷默:如何平衡呆在家裏和迴歸正常

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論